All
Chemo Led to Worse Survival, Response and Progression in R/R LBCL With CAR-T
December 21st 2023Patients with relapsed/refractory large B-cell lymphoma treated with CAR-T cell therapy and bendamustine chemotherapy, experienced lower rates of survival and response as well as shorter times until progression, according to recent study findings.
High Responses to Jaypirca in Relapsed CLL With BTK Mutations
December 20th 2023Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.
What Patients With Prostate Cancer Should Know About the EMBARK Trial
December 18th 2023Dr. Stephanie Berg of the Dana-Farber Cancer Institute and Harvard Medical School discussed the recent EMARK trial which resulted in the FDA’s approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis.
Arimidex/Faslodex And Enhertu Has Metastatic Breast Cancer Antitumor Activity
December 17th 2023Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according to data from the phase 1b DESTINY-Breast08 trial.
Giuliana Rancic Talks Breast Cancer Survivorship Insights
December 16th 2023“I have found many survivors to be very strong women who seem like they have things under control but it’s always important for family and friends to check in,” television personality, author and breast cancer survivor Giuliana Rancic told CURE.